Newsletter
Newsletter Support JNS
David Adler. Credit: Courtesy.

David Adler

Professor David Adler is a senior pharmaceutical leader in oncology clinical drug development and translational medicine. He spent a decade in senior leadership within Bayer AG’s Global Oncology Clinical Development organization and currently serves as chief scientific and medical officer of the PATHORA Institute of Pathology & Tissue Medicine, alongside academic appointments at the Hebrew University of Jerusalem, Ben-Gurion University of the Negev and the University of Bonn.

Governments and businesses must distinguish between permission to invest, international acceptance of the investment and the benefits delivered to local people.
We cannot yet quantify a Jewish biomedical brain drain, but waiting for measurable losses may mean responding too late.
A U.S.-sponsored Middle East pharmaceutical security framework would be a good place to start.
It may look like it sometimes, but these companies are actually gaining, not losing, value for Israel.
Biotechnology could serve as a foundation for normalization between the two countries.